Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Συντάκτης(Asc)] Τίτλος Τύπος Έτος
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Athyros, V. G., & Mikhailidis D. P. (2014).  Therapy: Caloric and fat intake in statin users.. Nat Rev Endocrinol. 10(8), 450-1.
Athyros, V. G., Pagourelias E. D., Gossios T. D., & Vasilikos V. G. (2015).  Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?. Curr Vasc Pharmacol. 13(3), 368-80.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Atorvastatin: safety and tolerability.. Expert Opin Drug Saf. 9(4), 667-74.
Athyros, V. G., Ganotakis E. S., Elisaf M. S., Liberopoulos E. N., Goudevenos I. A., & Karagiannis A. (2007).  Prevalence of vascular disease in metabolic syndrome using three proposed definitions.. Int J Cardiol. 117(2), 204-10.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Editorial: (Persistent elevation of blood pressure in children and adolescents is associated with arterial hypertension and premature atherosclerosis in adults. Is it possible to reverse this?).. Curr Vasc Pharmacol. 12(6), 870-2.
Athyros, V. Gabriel, Doumas M., & Karagiannis A. (2016).  Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action.. Indian Heart J. 68(5), 596-598.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother. 16(10), 1449-61.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?. Curr Pharm Des. 16(34), 3939-847.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Stage of chronic kidney disease and severity of coronary heart disease manifestation.. Expert Opin Pharmacother. 13(4), 457-60.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and non-alcoholic steatohepatitis.. J Hepatol. 64(1), 241-2.
Athyros, V. G., Karagiannis A., Hatzitolios A. I., Paletas K., Savopoulos C., Giannoglou G., et al. (2009).  Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study.. Curr Med Res Opin. 25(4), 971-80.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.. Expert Rev Cardiovasc Ther. 13(9), 1059-66.
Athyros, V. G., & Mikhailidis D. P. (2012).  Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate.. Nat Rev Endocrinol. 8(3), 133-4.
Athyros, V. G., Kakafika A. I., Karagiannis A., Koragiannis A., Mikhailidis D. P., & Mikhalidis D. P. (2008).  Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.. Am J Cardiol. 101(11), 1679-80.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Should raising high-density lipoprotein cholesterol be a matter of debate?. J Cardiovasc Med (Hagerstown). 13(4), 254-9.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. Curr Vasc Pharmacol. 14(1), 88-97.
Athyros, V. G., Katsiki N., & Doumas M. (2018).  Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.. Curr Vasc Pharmacol. 16(2), 104-106.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Athyros, V. G., Katsiki N., Karagiannis A., & Radak D. (2014).  Effect of Statins on rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy.. Curr Vasc Pharmacol.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.
Athyros, V. G., Kakafika A., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opin Investig Drugs. 17(4), 445-9.
Athyros, V. G., Doumas M., Imprialos K. P., Stavropoulos K., Georgianou E., Katsimardou A., et al. (2018).  Diabetes and lipid metabolism.. Hormones (Athens). 17(1), 61-67.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cold temperature and cardiovascular mortality.. Circ J. 77(11), 2846.
Athyros, V. G., Karagiannis A., Kakafika A., Elisaf M., & Mikhailidis D. P. (2007).  Statins and renal function. Is the compound and dose making a difference?. Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
Athyros, V. G., & Wierzbicki A. S. (2014).  Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low.. Curr Med Res Opin. 30(1), 57-8.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές